BioMarin Pharmaceutical (BMRN) ROIC: History & Chart

Name: BioMarin Pharmaceutical Inc. (BMRN) Return on Invested Capital (ROIC) — historical time series
Creator: TGMCharts

Compare

BioMarin Pharmaceutical Inc.(BMRN)

Biotechnology · San Rafael, CA

$56.24-1.30 (-2.26%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

Compare

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.

San Rafael, CA

3,221 employees

www.biomarin.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alexander Hardy

View full financials

BMRN Return on Invested Capital (ROIC) Metrics

RETURN ON INVESTED CAPITAL (ROIC)

1.40%

RETURN ON INVESTED CAPITAL (ROIC) AVG TTM

5.37%

RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y

4.39%

RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y

2.86%

RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y

0.85%

RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y

-1.36%

RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y

-1.47%

CURRENT VS TTM AVG

-73.89%

CURRENT VS 3Y AVG

-68.03%

CURRENT VS 5Y AVG

-50.93%

CURRENT VS 10Y AVG

+64.09%

CURRENT VS 15Y AVG

+202.81%

CURRENT VS 20Y AVG

+195.61%

SECTOR MEDIAN · HEALTHCARE

-34.77%

median of 763 covered companies

CURRENT VS SECTOR MEDIAN

+104.03%

vs the sector median at left

NAME	MARKET CAP	RETURN ON INVESTED CAPITAL (ROIC)	TTM	3Y	5Y
BioMarin Pharmaceutical Inc. (BMRN)	$10.87B	1.40%	5.37%	4.39%	2.86%
The Cooper Companies, Inc. (COO)vs ›	$10.98B	4.76%	4.09%	3.90%	4.30%
Universal Health Services, Inc. (UHS)vs ›	$10.65B	11.74%	10.95%	8.97%	9.05%
Globus Medical, Inc. (GMED)vs ›	$10.41B	10.49%	5.87%	5.79%	6.13%
ImmunityBio, Inc. (IBRX)vs ›	$10.36B	-45.63%	-80.95%	-90.71%	-98.29%
Bio-Techne Corporation (TECH)vs ›	$11.34B	7.86%	5.36%	7.03%	8.47%
Madrigal Pharmaceuticals, Inc. (MDGL)vs ›	$11.47B	-37.02%	-44.30%	-70.13%	-81.62%
Align Technology, Inc. (ALGN)vs ›	$10.19B	8.90%	10.00%	10.19%	11.72%
The Ensign Group, Inc. (ENSG)vs ›	$10.16B	7.29%	7.04%	6.95%	7.54%
Repligen Corporation (RGEN)vs ›	$10.08B	1.85%	0.17%	2.33%	3.34%

NAME

MARKET CAP

RETURN ON INVESTED CAPITAL (ROIC)

TTM

BioMarin Pharmaceutical Inc. (BMRN)

$10.87B

1.40%

5.37%

4.39%

2.86%

The Cooper Companies, Inc. (COO)vs ›

$10.98B

4.76%

4.09%

3.90%

4.30%

Universal Health Services, Inc. (UHS)vs ›

$10.65B

11.74%

10.95%

8.97%

9.05%

Globus Medical, Inc. (GMED)vs ›

$10.41B

10.49%

5.87%

5.79%

6.13%

ImmunityBio, Inc. (IBRX)vs ›

$10.36B

-45.63%

-80.95%

-90.71%

-98.29%

Bio-Techne Corporation (TECH)vs ›

$11.34B

7.86%

5.36%

7.03%

8.47%

Madrigal Pharmaceuticals, Inc. (MDGL)vs ›

$11.47B

-37.02%

-44.30%

-70.13%

-81.62%

Align Technology, Inc. (ALGN)vs ›

$10.19B

8.90%

10.00%

10.19%

11.72%

The Ensign Group, Inc. (ENSG)vs ›

$10.16B

7.29%

7.04%

6.95%

7.54%

Repligen Corporation (RGEN)vs ›

$10.08B

1.85%

0.17%

2.33%

3.34%

Return on Invested Capital (ROIC) Formula & Definition

ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)

Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.

Return on Invested Capital (ROIC) FAQ

What is the return on invested capital (ROIC) for BioMarin Pharmaceutical Inc. (BMRN)?

The return on invested capital (ROIC) for BMRN stock is 1.40%.

Is BioMarin Pharmaceutical Inc.'s return on invested capital (ROIC) high or low?

The return on invested capital (ROIC) of 1.40% is 51% below its 5-year average of 2.86%, near the low end of its 5-year range (-1.51%–8.97%).

What is the TTM average return on invested capital (ROIC) for BioMarin Pharmaceutical Inc. (BMRN)?

The TTM average return on invested capital (ROIC) for BMRN stock is 5.37%.

What is the 3Y average return on invested capital (ROIC) for BioMarin Pharmaceutical Inc. (BMRN)?

The 3Y average return on invested capital (ROIC) for BMRN stock is 4.39%.

What is the 5Y average return on invested capital (ROIC) for BioMarin Pharmaceutical Inc. (BMRN)?

The 5Y average return on invested capital (ROIC) for BMRN stock is 2.86%.

What is the 10Y average return on invested capital (ROIC) for BioMarin Pharmaceutical Inc. (BMRN)?

The 10Y average return on invested capital (ROIC) for BMRN stock is 0.85%.

What is the 15Y average return on invested capital (ROIC) for BioMarin Pharmaceutical Inc. (BMRN)?

The 15Y average return on invested capital (ROIC) for BMRN stock is -1.36%.

What is the 20Y average return on invested capital (ROIC) for BioMarin Pharmaceutical Inc. (BMRN)?

The 20Y average return on invested capital (ROIC) for BMRN stock is -1.47%.

DATE	RETURN ON INVESTED CAPITAL (ROIC)
2026-06-30	1.40%
2026-03-31	3.93%
2025-12-31	5.64%
2025-09-30	6.92%
2025-06-30	8.97%
2025-03-31	7.39%
2024-12-31	5.98%
2024-09-30	4.52%
2024-06-30	3.36%
2024-03-31	2.74%
2023-12-31	2.49%
2023-09-30	2.13%
2023-06-30	1.57%
2023-03-31	1.27%
2022-12-31	2.45%
2022-09-30	1.57%
2022-06-30	0.97%
2022-03-31	0.54%
2021-12-31	-1.51%
2021-09-30	-1.12%
2021-06-30	-1.17%
2021-03-31	-2.17%
2020-12-31	-0.69%
2020-09-30	-0.02%
2020-06-30	1.21%
2020-03-31	1.37%
2019-12-31	-2.44%
2019-09-30	-3.18%
2019-06-30	-3.77%
2019-03-31	-3.38%
2018-12-31	-3.16%
2018-09-30	-0.65%
2018-06-30	-0.60%
2018-03-31	-0.93%
2017-12-31	-0.35%
2017-09-30	-3.90%
2017-06-30	-5.73%
2017-03-31	-20.51%
2016-12-31	-22.28%
2016-09-30	-17.56%
2016-06-30	-23.09%
2016-03-31	-3.84%
2015-12-31	-3.37%
2015-09-30	-8.37%
2015-06-30	-5.38%
2015-03-31	-3.95%
2014-12-31	-4.15%
2014-09-30	-3.87%
2014-06-30	-6.81%
2014-03-31	-6.84%
2013-12-31	-7.57%
2013-09-30	-10.37%
2013-06-30	-7.56%
2013-03-31	-8.34%
2012-12-31	-7.75%
2012-09-30	-5.82%
2012-06-30	-6.25%
2012-03-31	-4.83%
2011-12-31	-2.80%
2011-09-30	-1.30%
2011-06-30	-0.19%
2011-03-31	0.00%
2010-12-31	0.05%
2010-09-30	0.89%
2010-06-30	2.15%
2010-03-31	2.44%
2009-12-31	1.08%
2009-09-30	4.34%
2009-06-30	3.53%
2009-03-31	3.47%
2008-12-31	4.33%
2008-09-30	-0.18%
2008-06-30	-2.68%
2008-03-31	-5.06%
2007-12-31	-7.51%
2007-09-30	-7.92%
2007-06-30	-6.19%
2007-03-31	-8.09%
2006-12-31	-5.82%
2006-09-30	-6.02%
2006-06-30	-8.00%
2006-03-31	-11.44%
2005-12-31	-38.62%
2005-09-30	-74.27%
2005-06-30	-106.42%
2005-03-31	-115.57%
2004-12-31	-87.19%
2004-09-30	-43.79%
2004-06-30	-36.67%
2004-03-31	-33.28%
2003-12-31	-31.13%
2003-09-30	-28.69%
2003-06-30	-24.50%

DATE

RETURN ON INVESTED CAPITAL (ROIC)

2026-06-30

1.40%

2026-03-31

3.93%

2025-12-31

5.64%

2025-09-30

6.92%

2025-06-30

8.97%

2025-03-31

7.39%

2024-12-31

5.98%

2024-09-30

4.52%

2024-06-30

3.36%

2024-03-31

2.74%

2023-12-31

2.49%

2023-09-30

2.13%

2023-06-30

1.57%

2023-03-31

1.27%

2022-12-31

2.45%

2022-09-30

1.57%

2022-06-30

0.97%

2022-03-31

0.54%

2021-12-31

-1.51%

2021-09-30

-1.12%

2021-06-30

-1.17%

2021-03-31

-2.17%

2020-12-31

-0.69%

2020-09-30

-0.02%

2020-06-30

1.21%

2020-03-31

1.37%

2019-12-31

-2.44%

2019-09-30

-3.18%

2019-06-30

-3.77%

2019-03-31

-3.38%

2018-12-31

-3.16%

2018-09-30

-0.65%

2018-06-30

-0.60%

2018-03-31

-0.93%

2017-12-31

-0.35%

2017-09-30

-3.90%

2017-06-30

-5.73%

2017-03-31

-20.51%

2016-12-31

-22.28%

2016-09-30

-17.56%

2016-06-30

-23.09%

2016-03-31

-3.84%

2015-12-31

-3.37%

2015-09-30

-8.37%

2015-06-30

-5.38%

2015-03-31

-3.95%

2014-12-31

-4.15%

2014-09-30

-3.87%

2014-06-30

-6.81%

2014-03-31

-6.84%

2013-12-31

-7.57%

2013-09-30

-10.37%

2013-06-30

-7.56%

2013-03-31

-8.34%

2012-12-31

-7.75%

2012-09-30

-5.82%

2012-06-30

-6.25%

2012-03-31

-4.83%

2011-12-31

-2.80%

2011-09-30

-1.30%

2011-06-30

-0.19%

2011-03-31

0.00%

2010-12-31

0.05%

2010-09-30

0.89%

2010-06-30

2.15%

2010-03-31

2.44%

2009-12-31

1.08%

2009-09-30

4.34%

2009-06-30

3.53%

2009-03-31

3.47%

2008-12-31

4.33%

2008-09-30

-0.18%

2008-06-30

-2.68%

2008-03-31

-5.06%

2007-12-31

-7.51%

2007-09-30

-7.92%

2007-06-30

-6.19%

2007-03-31

-8.09%

2006-12-31

-5.82%

2006-09-30

-6.02%

2006-06-30

-8.00%

2006-03-31

-11.44%

2005-12-31

-38.62%

2005-09-30

-74.27%

2005-06-30

-106.42%

2005-03-31

-115.57%

2004-12-31

-87.19%

2004-09-30

-43.79%

2004-06-30

-36.67%

2004-03-31

-33.28%

2003-12-31

-31.13%

2003-09-30

-28.69%

2003-06-30

-24.50%

Return on Invested Capital (ROIC): 1.40%

BMRN Return on Invested Capital (ROIC)

BMRN Average Return on Invested Capital (ROIC) Chart

BMRN Current vs Average Return on Invested Capital (ROIC) Chart

BMRN Return on Invested Capital (ROIC) Metrics

BMRN Competitors' Return on Invested Capital (ROIC)

Capital Efficiency

Return on Invested Capital (ROIC) Formula & Definition

Return on Invested Capital (ROIC) FAQ

BMRN Return on Invested Capital (ROIC) History

Related Metrics